QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:AMED

Amedisys (AMED) Stock Forecast, Price & News

$94.02
+0.10 (+0.11%)
(As of 09/25/2023 ET)
Compare
Today's Range
$93.50
$94.20
50-Day Range
$89.84
$94.08
52-Week Range
$69.36
$107.00
Volume
196,265 shs
Average Volume
521,142 shs
Market Capitalization
$3.07 billion
P/E Ratio
1,343.33
Dividend Yield
N/A
Price Target
$109.67

Amedisys MarketRank™ Forecast

Analyst Rating
Hold
2.23 Rating Score
Upside/​Downside
16.6% Upside
$109.67 Price Target
Short Interest
Bearish
5.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.22mentions of Amedisys in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
2.23%
From $4.48 to $4.58 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

748th out of 961 stocks

Home Health Care Services Industry

5th out of 7 stocks


AMED stock logo

About Amedisys (NASDAQ:AMED) Stock

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

AMED Price History

AMED Stock News Headlines

Amedisys (NASDAQ:AMED) Now Covered by Analysts at StockNews.com
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Short Interest in Amedisys, Inc. (NASDAQ:AMED) Grows By 20.4%
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Travis Messina named CEO of Regent Surgical Health
What 11 Analyst Ratings Have To Say About Amedisys
Amedisys: Q2 Earnings Snapshot
Amedisys (AMED) Tops Q2 Earnings Estimates
Jefferies Downgrades Amedisys (AMED)
Benchmark Downgrades Amedisys (AMED)
See More Headlines
Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Company Calendar

Last Earnings
7/26/2023
Today
9/25/2023
Next Earnings (Estimated)
10/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
Health Care Services
Sector
Medical
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
20,000
Year Founded
1982

Price Target and Rating

Average Stock Price Forecast
$109.67
High Stock Price Forecast
$165.00
Low Stock Price Forecast
$81.00
Forecasted Upside/Downside
+16.6%
Consensus Rating
Hold
Rating Score (0-4)
2.23
Research Coverage
13 Analysts

Profitability

Net Income
$118.61 million
Pretax Margin
2.18%

Debt

Sales & Book Value

Annual Sales
$2.22 billion
Cash Flow
$7.25 per share
Book Value
$34.06 per share

Miscellaneous

Free Float
32,046,000
Market Cap
$3.07 billion
Optionable
Optionable
Beta
1.00

Social Links

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Scott G. GinnMr. Scott G. Ginn (Age 54)
    Exec. VP, COO, CFO & Principal Financial Officer
    Comp: $659.94k
  • Mr. Michael P. NorthMr. Michael P. North (Age 58)
    Chief Information Officer
    Comp: $442.38k
  • Ms. Denise  BohnertMs. Denise Bohnert (Age 45)
    Chief Compliance Officer
    Comp: $399.72k
  • Mr. Nick Muscato (Age 37)
    Chief Strategy Officer
    Comp: $400.94k
  • Mr. Richard M. Ashworth (Age 48)
    Pres, CEO & Director
  • Ms. Allyson Guidroz
    Chief Accounting Officer & Principal Accounting Officer
  • Mr. Pete Hartley
    CTO & Sr. VP of Bus. Operations Systems
  • Ms. Jennifer Guckert Griffin
    Sr. VP, Deputy Gen. Counsel, Corp. Sec. & Interim Chief Legal Officer
  • Kendra Kimmons
    VP of Marketing & Communications & Media Relations
  • Mr. Adam Holton (Age 52)
    Chief People Officer













AMED Stock - Frequently Asked Questions

Should I buy or sell Amedisys stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 10 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings
or view top-rated stocks.

What is Amedisys' stock price forecast for 2023?

13 brokers have issued 12-month price targets for Amedisys' stock. Their AMED share price forecasts range from $81.00 to $165.00. On average, they expect the company's share price to reach $109.67 in the next year. This suggests a possible upside of 16.6% from the stock's current price.
View analysts price targets for AMED
or view top-rated stocks among Wall Street analysts.

How have AMED shares performed in 2023?

Amedisys' stock was trading at $83.54 on January 1st, 2023. Since then, AMED stock has increased by 12.5% and is now trading at $94.02.
View the best growth stocks for 2023 here
.

Are investors shorting Amedisys?

Amedisys saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 1,650,000 shares, an increase of 20.4% from the August 15th total of 1,370,000 shares. Based on an average daily volume of 465,500 shares, the short-interest ratio is currently 3.5 days. Currently, 5.2% of the shares of the stock are short sold.
View Amedisys' Short Interest
.

When is Amedisys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 25th 2023.
View our AMED earnings forecast
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) issued its quarterly earnings data on Wednesday, July, 26th. The health services provider reported $1.37 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.28. The health services provider earned $552.97 million during the quarter, compared to analyst estimates of $568.18 million. Amedisys had a trailing twelve-month return on equity of 14.00% and a net margin of 0.10%. The business's quarterly revenue was down .9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.47 earnings per share.

What ETFs hold Amedisys' stock?
What is Paul B. Kusserow's approval rating as Amedisys' CEO?

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.92%), Riverbridge Partners LLC (4.79%), JPMorgan Chase & Co. (3.36%), Mackenzie Financial Corp (2.89%), State Street Corp (2.85%) and Dimensional Fund Advisors LP (2.21%). Insiders that own company stock include Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter and Scott G Ginn.
View institutional ownership trends
.

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $94.02.

How much money does Amedisys make?

Amedisys (NASDAQ:AMED) has a market capitalization of $3.07 billion and generates $2.22 billion in revenue each year. The health services provider earns $118.61 million in net income (profit) each year or $0.07 on an earnings per share basis.

How many employees does Amedisys have?

The company employs 20,000 workers across the globe.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.

This page (NASDAQ:AMED) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -